Tabsuglip M 500mg/50mg Tablet

Tabsuglip M 500mg 50mg Tablet is an oral anti-diabetic combination medication containing Metformin (a biguanide) and Vildagliptin (a DPP-4 inhibitor). It is used to improve glycaemic control in adults with type 2 diabetes mellitus, particularly when blood sugar levels are not adequately managed with metformin alone or when combination therapy is required. By combining two agents with complementary mechanisms, Tabsuglip M 500mg 50mg Tablet helps lower both fasting and postprandial (after-meal) blood glucose levels. It is primarily available as oral tablets and is intended for use alongside a healthy diet and regular exercise.

Tabsuglip M 500mg 50mg Tablet is a fixed‑dose oral anti‑diabetic combination containing Metformin hydrochloride (a biguanide) and Vildagliptin (a dipeptidyl peptidase‑4 [DPP‑4] inhibitor). It is prescribed for the management of type 2 diabetes mellitus in adults, especially when Metformin alone does not provide adequate glycaemic control or when combination therapy is clinically appropriate.

Metformin lowers blood glucose by reducing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. Vildagliptin inhibits the DPP‑4 enzyme, prolonging incretin activity, which increases insulin secretion and decreases glucagon release in a glucose‑dependent manner. Together, these complementary mechanisms reduce both fasting plasma glucose and postprandial (after‑meal) glucose levels, improving overall glycaemic control.

This Tabsuglip M 500mg 50mg Tablet is typically available as oral tablets and is taken under the supervision of your doctor, who adjusts the dosage based on clinical response and tolerability. It is intended for use alongside dietary management and regular physical activity as part of a comprehensive diabetes care plan.

Tabsuglip M 500mg 50mg Tablet may be indicated by your doctor for:

Type 2 Diabetes Mellitus

To improve blood sugar control in adults whose glucose levels remain high despite diet, exercise, and treatment with metformin alone.

Combination Therapy

As an initial treatment in patients with type 2 diabetes when a single drug is unlikely to achieve target glucose levels.

Replacement Therapy

For patients already taking metformin and vildagliptin as separate tablets, to simplify their medication regimen.

Tabsuglip M 500mg 50mg Tablet may provide benefits such as:

• Comprehensive glucose control by targeting both the liver's glucose production and the pancreas's insulin response.

• Lower risk of hypoglycaemia compared to some other classes of diabetes medications like sulfonylureas.

• Weight-neutral profile, meaning it generally does not cause the weight gain associated with some other anti-diabetic drugs.

• Convenience of a single tablet, which improves adherence to the prescribed treatment plan.

• Reduction in HbA1c levels, helping to lower the long-term risk of diabetic complications like nerve, eye, or kidney damage.

Tabsuglip M 500mg 50mg Tablet is generally well-tolerated, but some side effects may occur as the body adjusts to the medication.

Common side effects of Tabsuglip M 500mg 50mg Tablet may include

• Nausea or vomiting

• Diarrhoea or abdominal pain

• Loss of appetite

• Metallic taste in the mouth

• Headache or dizziness

Uncommon side effects of Tabsuglip M 500mg 50mg Tablet may include

• Constipation

• Swelling of the hands or feet (oedema)

• Joint pain

• Fatigue

Serious side effects that may require immediate medical attention include

• Lactic Acidosis: A rare but serious build-up of acid in the blood (symptoms include severe exhaustion, muscle pain, or difficulty breathing).

• Pancreatitis: Severe and persistent stomach pain that may radiate to the back.

• Liver Dysfunction: Yellowing of the skin or eyes, dark urine, or persistent nausea.

• Severe Skin Reactions: Blistering or peeling of the skin.

• Hypoglycaemia: Excessive sweating, shakiness, or confusion (usually only when used with other diabetes drugs like insulin).

Always consult your doctor if you notice any unusual symptoms while taking Tabsuglip M 500mg 50mg Tablet.

Use Tabsuglip M 500mg 50mg Tablet exactly as directed by your doctor.

• Take orally with water. Swallow the tablet whole; do not crush or chew.

• Use with meals. Taking the medicine during or after food helps reduce stomach upset.

• Follow your doctor’s supervision. Your doctor prescribes the dose and adjusts it based on your blood sugar response and how well you tolerate the medicine.

• Maintain lifestyle measures. Continue with a balanced diet and regular exercise as advised by your healthcare provider.

• Do not self‑adjust. Never change the dose or stop the medicine without consulting your doctor.

Tabsuglip M 500mg 50mg Tablet works through two different paths. Metformin acts as an "insulin sensitiser"; it stops the liver from overproducing glucose and helps the muscles and fat cells absorb sugar from the blood more easily. Vildagliptin acts as a "DPP-4 inhibitor"; it protects the body's natural incretin hormones from being broken down. These hormones signal the pancreas to release more insulin when you eat and prevent the liver from releasing stored sugar into the blood. Together, they lower blood sugar levels throughout the day and night.

• Always carry a source of fast-acting sugar (like glucose tablets or candy) in case you experience symptoms of low blood sugar.

• Your doctor will likely order regular blood tests to check your kidney function and liver enzymes while you are on this medication.

• Inform any doctor or dentist treating you that you are taking metformin, especially if you are scheduled for surgery or a scan involving contrast dye.

• Stay well-hydrated, especially during illnesses involving vomiting or diarrhoea, to prevent kidney strain.

Store Tabsuglip M 500mg 50mg Tablet at room temperature (below 30°C) in a dry place away from direct sunlight and moisture.

• Keep the tablets in their original blister packaging until you are ready to take them.

• Do not store in the bathroom or near a sink.

• Keep out of the reach of children and pets.

• Do not use after the expiry date.

• Food: Taking the medication with food is recommended to minimize gastrointestinal discomfort.
• Alcohol (SEVERE): Significantly increases the risk of lactic acidosis and can cause unpredictable changes in blood sugar levels.

• ACE Inhibitors / NSAIDs (CAUTION): These medicines may affect kidney clearance and increase Metformin exposure. Your doctor may check kidney function more closely if these are used together.

• Hepatotoxic Drugs (CAUTION): Vildagliptin has been linked to rare cases of liver changes. If used with other medicines that affect the liver, your doctor may recommend periodic liver function tests.

• Iodinated Contrast Media (SEVERE): Tabsuglip M 500mg 50mg Tablet should be temporarily stopped before and after certain imaging procedures (such as CT scans or X‑rays with contrast dye). This precaution protects kidney function. Treatment can be restarted once your doctor confirms kidney function is stable.

• Kidney Disease (MODERATE/SEVERE): Metformin can accumulate in the body if the kidneys are not working well, increasing the risk of lactic acidosis.

• Liver Disease (SEVERE): Vildagliptin and Metformin should be avoided in patients with hepatic impairment.

• Heart Failure (CAUTION): Use with care in patients with unstable heart failure.

• Dehydration (CAUTION): Increases the risk of kidney issues while taking Metformin.

Taking more than the prescribed dose of this medicine can be harmful. In rare cases, it may lead to low blood sugar or a condition called lactic acidosis. Signs to watch for include unusual tiredness, rapid breathing, or changes in skin color. If an overdose is suspected, seek emergency medical help immediately.

If you miss a dose, take it as soon as you remember with food. If it is almost time for your next dose, skip the missed one and continue with your regular schedule. Do not take a double dose to make up for a missed one.